Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
Second Circuit upholds insider trading conviction of former Congressman
March 26, 2025
News Alert
Two foreign nationals charged in the United States for roles in an international insider trading scheme
March 19, 2025
News Alert
Former Biopharma executive in California settles insider trading charges
March 12, 2025
News Alert